The authors call for close monitoring of renal function and serum electrolyte and cation levels in patients beginning tenofovir with any of these drugs, in the hopes that early diagnosis of ...

As of September 2024, Medicare has covered FDA-approved Pre-exposure Prophylaxis (PrEP) oral or injectable antiretroviral drugs such as Truvada, as well as counseling sessions for HIV risk ...

As a stand-alone drug, tenofovir alafenamide fumarate has received full FDA approval to treat chronic hepatitis B but only tentative FDA approval to treat HIV. A person with HIV who takes ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Merck & Co Inc (NYSE:MRK) announced the presentation of results from two Phase 3 trials of doravirine/islatravir (DOR/ISL) in ...

Of the 22 FDC drugs approved for use in the United States, 14 are all-in-one treatments taken once daily. Fixed-Dose Combination (FDC) Drugs Brand Name Contents Typical Adult Dosage Dietary Notes ...

As with other drugs, Descovy (emtricitabine/tenofovir alafenamide) can cause side effects, such as liver or kidney problems. If you are not able to tolerate side effects of Descovy, talk with your ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

Cheap copies of Gilead’s HIV drug Truvada, which can also be used to reduce the risk of people becoming infected, could be available in the UK following a court ruling.

which will be looking to mitigate an anticipated drop in sales for its HIV portfolio owing to an erosion of market share for the Atripla franchise due to competition from other drugs and the ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

Tenofovir disoproxil fumarate (TDF ... half-life of approximately 150 hours versus 39 hours for FTC. Both drugs are concentrated in genital secretions as compared to plasma which is desirable ...